AlgoTx

Biotechnology ResearchÎle-de-france, France2-10 Employees

AlgoTx is a biotechnology company focused on developing targeted, pioneering therapies for peripheral neuropathic pain. Its lead candidate, ATX01, is a non-opioid therapy designed to act locally and relieve chemotherapy-induced peripheral neuropathy by selectively inhibiting pain-related sodium channels. Based in Suresnes, Île-de-France, the company has a small team supported by an international board of leaders. The ACT study is an international Phase II trial with more than 270 patients, and results are expected in early 2025, with plans to accelerate toward a Phase III program. In 2023, AlgoTx received France Biotech's ESG HealthTech Trophy for its early commitment to ESG initiatives.

Sign up for free to view info

Email Format Employee directory